Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.31 |
| ▸ | PRKCI | P41743 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2174853 | 0.82 | ALDH1A1 (0.52) | ALDH1A1TSHR | |
| SCHEMBL18932612 | 0.79 | PYCR1 (0.39) | ALDH1A1TSHRPYCR1ACHECYP11B1 | |
| SCHEMBL23562 | 0.74 | ALDH1A1 (0.60) | ALDH1A1TSHRACHE | |
| SCHEMBL18138033 | 0.74 | CYP2D6 (0.37) | ALDH1A1PYCR1 | |
| SCHEMBL3146615 | 0.73 | CHRNB2 (0.50) | CHRNB2CHRNA4PYCR1CYP11B1CYP11B2 | |
| SCHEMBL1098664 | 0.73 | ALDH1A1 (0.41) | ALDH1A1TSHR | |
| SCHEMBL14088678 | 0.72 | ALDH1A1 (0.63) | ALDH1A1TSHRACHECYP11B1CYP11B2 | |
| SCHEMBL1175842 | 0.72 | KDM4E (0.39) | ALDH1A1 | |
| SCHEMBL1175752 | 0.72 | TPMT (0.52) | ALDH1A1 | |
| SCHEMBL3148019 | 0.71 | MAPT (0.52) | ALDH1A1TSHRCHRNB2CHRNA4PYCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | PLE PATRICK | 2009-02-05 | — | — | US | disclosed |
| EP-1802608-A1 | QUINAZOLINE DERIVATIVES FOR USE AGAINST CANCER | AstraZeneca AB (SE) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006040526-A1 | QUINAZOLINE DERIVATIVES FOR USE AGAINST CANCER | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | AQP3, AQP1, F12 | ALDH1A1 2449/4885TSHR 2524/4885CHRNB2 3994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.